Welcome to our dedicated page for Zentalis Pharmaceuticals SEC filings (Ticker: ZNTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Zentalis Pharmaceuticals鈥� disclosures is no small task鈥攅ach 10-K details years of oncology R&D on its lead WEE1 inhibitor, azenosertib, alongside complex milestone obligations and dilution risks. If you have ever tried to locate trial spend or option-exercise clauses buried in hundreds of pages, you know the challenge of Zentalis SEC filings explained simply.
Stock Titan鈥檚 AI tackles that complexity head-on. Our engine delivers real-time alerts the moment a Zentalis Form 4 insider transactions real-time notice posts, highlights cash-runway updates in every Zentalis quarterly earnings report 10-Q filing, and delivers a plain-English breakdown of the Zentalis annual report 10-K simplified. Need the fine print on board pay? We surface the figures straight from the Zentalis proxy statement executive compensation. Curious about sudden trial news? Click into the Zentalis 8-K material events explained card and see what shifted鈥攚ithout reading pages of legal text.
Whether you are monitoring Zentalis insider trading Form 4 transactions, comparing R&D trends with our Zentalis earnings report filing analysis, or simply understanding Zentalis SEC documents with AI, the platform keeps critical data at your fingertips. You鈥檒l receive:
- Immediate alerts on Zentalis executive stock transactions Form 4
- AI-powered summaries that spotlight trial milestones and collaboration fees
- Side-by-side views of consecutive filings for faster quarter-over-quarter checks
Zentalis Pharmaceuticals (ZNTL) Director Luke Nathaniel Walker received a grant of 57,603 restricted stock units (RSUs) on June 17, 2025, as part of the company's Non-Employee Director Compensation Program. Following this transaction, Walker's direct ownership increased to 144,284 shares.
Key details of the RSU grant:
- Each RSU represents a contingent right to receive one share of common stock
- Vesting occurs at the earlier of June 17, 2026, or the next annual stockholder meeting
- Vesting is contingent on continued service on the Board of Directors
- The RSUs were granted at $0 cost to the director
The transaction was reported via Form 4 filing and was executed through an attorney-in-fact, Andrea Paul, on June 18, 2025. This equity grant aligns with standard director compensation practices and serves to strengthen the alignment between director and shareholder interests.
Zentalis Pharmaceuticals (ZNTL) Director Jan Skvarka received a grant of 57,603 restricted stock units (RSUs) on June 17, 2025, as part of the company's Non-Employee Director Compensation Program. Following this transaction, Skvarka now beneficially owns 207,154 shares directly.
Key details of the RSU grant:
- Each RSU represents a contingent right to receive one share of common stock
- Vesting occurs at the earlier of June 17, 2026 or the next annual stockholder meeting
- Vesting is contingent on continued service on the Board of Directors
- The RSUs were granted at $0 exercise price
This Form 4 filing was submitted by Andrea Paul as attorney-in-fact for Jan Skvarka on June 18, 2025, in compliance with SEC insider trading reporting requirements.
Zentalis Pharmaceuticals (ZNTL) Director David Michael Johnson reported acquiring 57,603 restricted stock units (RSUs) on June 17, 2025. The RSUs were granted under the company's Non-Employee Director Compensation Program at a price of $0.
Key details of the transaction:
- Following the transaction, Johnson directly owns 250,421 shares
- The RSUs will vest on the earlier of June 17, 2026 or the next annual stockholder meeting
- Vesting is contingent on Johnson's continued service on the Board of Directors
- Each RSU represents the right to receive one share of common stock upon vesting
The Form 4 was filed on June 28, 2025, with the signature executed by Andrea Paul as attorney-in-fact for David M. Johnson on June 18, 2025.
Zentalis Pharmaceuticals (NASDAQ: ZNTL) held its 2025 Annual Meeting of Stockholders on June 17, with 80.9% of outstanding shares represented. Key voting results include:
- Director Elections: Three Class II directors were elected to serve until 2028: - Scott Myers (43M votes for) - Karan Takhar (30.7M votes for) - Luke Walker, M.D. (36.6M votes for)
- Auditor Ratification: Ernst & Young LLP appointment was approved with overwhelming support (58.1M votes for, representing 99.8% approval)
- Executive Compensation: The "Say-on-Pay" vote passed but with significant opposition - 62.9% in favor (29.5M votes) versus 37.1% against (17.4M votes), indicating substantial shareholder concerns about executive compensation practices
The meeting results suggest strong shareholder engagement but reveal notable dissent regarding executive compensation and varying levels of support for board nominees, particularly for Karan Takhar who received the lowest approval rate among directors.
FAQ
What is the current stock price of Zentalis Pharmaceuticals (ZNTL)?
What is the market cap of Zentalis Pharmaceuticals (ZNTL)?
What is the primary focus of Zentalis Pharmaceuticals?
What role does the Integrated Discovery Engine play in their operations?
What is azenosertib and how is it significant?
Which types of cancers are being targeted by Zentalis鈥� clinical programs?
How does the company utilize biomarker-enrichment strategies?
How does Zentalis differentiate itself in the competitive oncology landscape?
What are the key advantages of small molecule therapeutics developed by Zentalis?
What insights can investors gain from Zentalis鈥� clinical trial progress?
